Skip to main content
Premium Trial:

Request an Annual Quote

Invitae Acquires Ommdom's CancerGene Connect

NEW YORK (GenomeWeb) – Invitae said today that it has acquired health software developer Ommdom and its genomic management tool CancerGene Connect, an end-to-end platform for collecting and managing genetic family histories.

Under the terms of the agreement, Invitae acquired all Ommdom's outstanding capital stock in exchange for approximately $6 million in Invitae common stock.

According to Invitae, the acquisition expands its existing suite of technologies that help patients and clinicians use genetic information as part of mainstream medical care.

"The CancerGene Connect platform is unmatched for ease of use and depth of analysis, and has strong endorsement from clinicians who use it," Invitae CEO Sean George said in a statement.

Initially developed at UT Southwestern, CancerGene Connect is a cloud-based, mobile-friendly patient interface that prompts and guides users to gather their family history information prior to an appointment with a clinician.

Once an individual completes entering their information, clinicians can then use the platform to evaluate hereditary risk, analyze a patient's predisposition to disease, and make decisions about further genetic testing or medical treatment. Physicians can also access data and study trends across all their patients that have used the portal.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.